Research progress of increased heart rate related to glucagon-like peptide-1 receptor agonists
10.3760/cma.j.cn114015-20240508-00315
- VernacularTitle:胰高血糖素样肽-1受体激动剂相关心率加快的研究进展
- Author:
Li WANG
1
;
Xusheng ZHANG
1
;
Xiuli REN
1
;
Chengwu SHEN
1
;
Cuicui LU
1
Author Information
1. 山东第一医科大学附属省立医院药学部，济南 250021
- Publication Type:Journal Article
- Keywords:
Glucagon-like peptide-1;
Diabetes mellitus, type 2;
Heart rate;
Drug-related side effects and adverse reactions;
Glucagon-like peptide-1 receptor agonists
- From:
Adverse Drug Reactions Journal
2025;27(3):182-187
- CountryChina
- Language:Chinese
-
Abstract:
Glucagon-like peptide-1 receptor agonists (GLP-1RA) have been widely used in the treatment of type 2 diabetes mellitus (T2DM). However, the acceleration of heart rate caused by GLP-1RA should not be ignored. In the general population and patients with diabetes, increased heart rate has an independent correlation with the incidence and mortality of cardiovascular diseases. In general, the long-acting GLP-1RA seem to exert a greater effect in increasing heart rate, and the effect is dose-dependent and negatively correlated with baseline heart rate. The increase in heart rate caused by GLP-1RA may be related to enhanced sympathetic nervous activity, reflex tachycardia as a response to vasodilation, etc. It is advisable to closely monitor the increased heart rate induced by GLP-1RA in clinical practice, especially in patients with high-risk factors for cardiovascular disease. In case of elevated heart rate, the management begins with immediate discontinuation of the GLP-1RA and symptomatic intervention should be given if necessary.
